If you’ve been waiting for the right moment to invest in cannabis, 2026 might be the year that changes everything.
The best marijuana stocks to buy in 2026 aren’t just riding on legalization hopes anymore. They’re backed by real revenues, improving margins, and — for the first time — a credible shot at federal rescheduling in the United States. That single catalyst could unlock billions in institutional capital, slash the industry’s brutal 280E tax burden, and finally give cannabis companies access to proper banking.
But here’s the catch: not every cannabis stock is worth your money. The sector is littered with companies that burn cash, carry dangerous debt loads, and have no clear path to profitability. You need to separate the winners from the wishful thinkers.
That’s exactly what this list does.
📈 RESEARCH ALL 10 CANNABIS STOCKS IN REAL TIME
Compare charts, financial statements, analyst ratings, earnings data, and market performance for every cannabis stock on this list. TradingView gives you the research tools used by millions of investors worldwide — all in one place.
TRADINGVIEW — TRY IT FREE →Why 2026 Is a Critical Year for Marijuana Stocks
The cannabis sector has disappointed investors before. Multiple times, actually. So why is 2026 different?
The short answer is federal rescheduling. The U.S. Drug Enforcement Administration (DEA) is progressing through the process of moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. That might sound like bureaucratic noise, but the financial implications are massive.
Right now, cannabis companies operating in the U.S. cannot deduct normal business expenses from their taxable income. This is thanks to Section 280E of the IRS tax code, which applies to businesses trafficking in Schedule I or II controlled substances. Rescheduling to Schedule III would eliminate 280E entirely — instantly improving profitability for every major multi-state operator (MSO) without a single dollar of new revenue.
Add to that the growing momentum for SAFE Banking Act legislation, which would give cannabis businesses proper access to financial institutions, and you start to understand why institutional investors are paying very close attention to this sector in 2026.
The U.S. legal cannabis market is projected to exceed $47 billion in 2026. The question is whether you’re positioned for it.
How We Ranked These Marijuana Stocks
Every stock on this list was evaluated across six factors: market leadership, revenue scale, profitability potential, U.S. reform exposure, balance sheet strength, and analyst sentiment. No pure speculation plays made the cut — only companies that can survive, and thrive, regardless of how fast federal reform moves.
#10 — Planet 13 Holdings (PLNH)
Planet 13 is unlike any other cannabis company on this list. Its flagship Las Vegas dispensary — essentially a cannabis entertainment superstore spanning over 112,000 square feet — is genuinely one of the most visited cannabis destinations in the world.
The Las Vegas tourism angle is both its greatest strength and its biggest risk. The company draws massive foot traffic from visitors who would never buy cannabis at home, generating strong brand loyalty and higher ticket sales. Planet 13 is now expanding into new states, reducing its tourism dependency and building a more diversified retail footprint.
For investors who want exposure to a unique, experience-driven cannabis brand rather than just another MSO, Planet 13 is the most differentiated pick on this list.
Why It Made the List: Unique superstore model, expanding beyond Nevada, strong brand recognition
Risks: Smaller scale, heavy reliance on Las Vegas tourism
#9 — Jushi Holdings (JUSHF)
If you’re looking for undervalued cannabis plays, Jushi Holdings has been consistently underpriced relative to its assets and market exposure. The company operates in some of the most important emerging cannabis states, including Pennsylvania, Virginia, and Ohio — all of which have seen significant market growth.
Jushi is also frequently mentioned as a potential acquisition target, which means investors could benefit from a takeover premium if cannabis M&A activity picks up alongside federal reform. That optionality is hard to price, but it’s real.
The main caveat is leverage — Jushi carries more debt than some peers, which limits financial flexibility. But for risk-tolerant investors, the upside is compelling.
Why It Made the List: Undervalued, exposure to emerging markets, potential takeover candidate
Risks: Higher leverage, execution risk
#8 — TerrAscend (TSNDF)
TerrAscend is quietly building one of the stronger operational track records in the multi-state cannabis space. Its core markets — New Jersey and Pennsylvania — are among the most profitable in the country, and the company has been consistently improving margins over the past several quarters.
What makes TerrAscend interesting in 2026 is its focused approach: rather than expanding aggressively and burning cash, the company has prioritized operational discipline and is seeing the payoff in improved unit economics. It’s not the flashiest cannabis stock on this list, but that’s kind of the point.
Why It Made the List: Strong operations in NJ and PA, improving margins, solid U.S. exposure
Risks: Competitive markets, ongoing regulatory uncertainty
#7 — Glass House Brands (GLASF)
Glass House Brands is one of the most intriguing cannabis companies for a very specific reason: it operates one of the largest greenhouse cultivation platforms in the United States, giving it a massive cost advantage over competitors.
The company grows cannabis in a 5.5 million square foot greenhouse in California, which allows it to produce large volumes at a cost per gram that’s a fraction of what indoor cultivators pay. If interstate commerce for cannabis ever becomes legal — a real possibility if rescheduling progresses — Glass House would be extraordinarily well positioned to supply dispensaries nationwide.
Glass House is now among the larger holdings of the cannabis-focused MSOS ETF, reflecting growing institutional interest in the company.
Why It Made the List: Dominant low-cost cultivation model, interstate commerce optionality, high growth profile
Risks: California’s retail cannabis market remains challenging due to illicit market competition
#6 — Village Farms International (VFF)
Village Farms is the most diversified company on this list. Unlike pure cannabis plays, Village Farms is a commercial greenhouse producer with operations in vegetables, cannabis, and other agricultural products. That diversification actually works in its favor — the company can weather cannabis market volatility better than single-focused MSOs.
Its Canadian cannabis operations are mature and profitable, and the company has avoided the reckless expansion that destroyed many early cannabis companies. Village Farms remains one of the largest non-MSO cannabis holdings in major cannabis ETFs, which speaks to its credibility among institutional investors.
Why It Made the List: Diversified agricultural model, strong Canadian cannabis operations, financially conservative
Risks: Slower growth profile than pure-play U.S. MSOs
📈 TRACK ALL THESE CANNABIS STOCKS IN REAL TIME
Monitor cannabis stocks with real-time charts, financial statements, analyst ratings, earnings data, and custom watchlists. TradingView gives you everything you need to research and track opportunities from a single platform.
TRADINGVIEW — TRY IT FREE →#5 — Cresco Labs (CRLBF)
Cresco Labs has built something unique in the cannabis industry: a leading wholesale distribution platform that supplies its branded products to dispensaries across the country — not just its own stores. This B2B model gives Cresco a revenue stream that’s less dependent on retail foot traffic and more scalable across new markets.
The company operates a large footprint across multiple states and is a consistent top-five holding in MSOS, the most prominent cannabis-focused ETF. The main headwind is industry-wide pricing pressure, which has squeezed margins across the sector. But if rescheduling removes the 280E burden, Cresco’s wholesale model could see a dramatic jump in profitability.
Why It Made the List: Leading wholesale platform, multi-state scale, strong upside from federal reform
Risks: Ongoing industry-wide pricing pressure
#4 — Verano Holdings (VRNOF)
Verano Holdings is one of the most consistently undervalued large MSOs in the U.S. cannabis market. It operates a strong retail network across multiple states with a track record of operational execution that rivals much larger peers, yet it trades at a discount to companies with fewer dispensaries and less cash generation.
That valuation gap may not last long. Verano is one of the top holdings in cannabis-focused ETFs and is frequently cited by analysts as a primary beneficiary of U.S. cannabis reform. For investors looking for a margin of safety alongside cannabis upside, Verano offers one of the better risk-adjusted profiles in the sector.
Why It Made the List: Consistent operations, strong retail network, attractive valuation
Risks: Limited institutional ownership compared to top-tier peers
#3 — Trulieve Cannabis (TCNNF)
If one cannabis company stands to benefit most from a single state-level catalyst, it’s Trulieve. The company dominates the Florida cannabis market with a market share that no competitor has come close to matching — and Florida is on the verge of potentially becoming the largest cannabis market in the United States.
Trulieve already generates substantial free cash flow, which is rare in this industry. And should Florida advance recreational cannabis in the coming legislative cycles, Trulieve’s existing infrastructure — retail locations, cultivation facilities, processing plants — positions it to capture the majority of that new demand overnight.
Trulieve is currently the largest holding within the AdvisorShares Pure U.S. Cannabis ETF (MSOS), highlighting its dominant position in the sector.
Why It Made the List: Dominant Florida market position, strong cash generation, massive upside from recreational expansion
Risks: Geographic concentration in a single state
#2 — Curaleaf Holdings (CURLF)
Curaleaf is the largest cannabis company in the United States by revenue and retail footprint. It operates dispensaries across more states than any other MSO and has made significant strides in international expansion — giving it exposure to European and other global cannabis markets that are still in early growth phases.
The scale is both its greatest asset and a source of complexity. Operating across so many regulatory environments requires significant management bandwidth, and execution risks are higher at this size. But for investors who want maximum exposure to U.S. cannabis reform with some global optionality, Curaleaf is the only large-cap cannabis stock that checks both boxes.
Curaleaf remains among the largest positions across cannabis-focused investment funds and is viewed by many analysts as the default blue-chip cannabis stock.
Why It Made the List: Largest U.S. cannabis company, extensive retail network, international expansion
Risks: Regulatory complexity at scale
#1 — Green Thumb Industries (GTBIF)
Green Thumb Industries is, by almost every measure, the highest-quality operator in the U.S. cannabis industry. It has achieved something that most cannabis companies have only promised: consistent profitability.
While competitors were burning cash to expand, Green Thumb was building sustainable unit economics, generating free cash flow, and maintaining a conservative balance sheet. The company operates across multiple high-value states with a portfolio of strong house brands and well-positioned retail locations.
What sets Green Thumb apart in 2026 is that it doesn’t need federal reform to succeed — but if rescheduling happens, the 280E relief will flow straight to the bottom line of a company that’s already making money. That combination of defensibility and upside is exactly what serious investors should be looking for in a cannabis stock.
Among cannabis investors, Green Thumb is consistently viewed as the best risk-adjusted play in the sector, and analyst commentary has reinforced that view heading into 2026.
Why It’s the Best Marijuana Stock for 2026: Consistent profitability, strong cash flow, conservative balance sheet, best-in-class management
Risks: Trades at a premium to peers — the quality justifies it
Best Marijuana Stocks by Investment Style
| Investment Goal | Best Stock |
|---|---|
| Best Overall | Green Thumb Industries (GTBIF) |
| Highest Growth | Glass House Brands (GLASF) |
| Largest Operator | Curaleaf Holdings (CURLF) |
| Best Florida Play | Trulieve Cannabis (TCNNF) |
| Best Value | Verano Holdings (VRNOF) |
| Most Diversified | Village Farms International (VFF) |
| Potential Turnaround | Cresco Labs (CRLBF) |
Biggest Cannabis Catalysts for the Rest of 2026
The stocks on this list don’t move in a vacuum. Here are the five catalysts that could move the entire cannabis sector significantly in the months ahead.
Federal rescheduling implementation is the most important one to watch. If the DEA finalizes the move to Schedule III, the 280E tax relief alone could add tens of millions in net income to every major MSO overnight — the single biggest binary catalyst for the entire sector.
Banking reform is the second-most important driver. SAFE Banking legislation would allow cannabis companies to access traditional financial services — reducing their cost of capital, improving cash management, and opening the door for institutional investors currently restricted from holding cannabis positions.
Additional state legalization measures continue to expand the total addressable market, with particular attention on emerging markets in the Southeast and Mid-Atlantic. Growth in medical cannabis markets internationally is also creating new revenue streams, which companies like Curaleaf are already capitalizing on.
If you want to diversify across multiple sectors during this period of market uncertainty, it’s worth reading about 10 best industrials stocks to buy and 10 best healthcare stocks to buy — both sectors have shown resilience during periods of cannabis market volatility.
📈 TRACK EVERY CATALYST AND PRICE MOVE ACROSS ALL 10 CANNABIS STOCKS
Stay ahead of earnings releases, regulatory developments, analyst upgrades, and major market moves with real-time charts, financial data, custom watchlists, and powerful research tools. TradingView helps you monitor every stock on your cannabis watchlist from one platform.
TRADINGVIEW — TRY IT FREE →The Conservative Option: MSOS ETF
Not ready to pick individual cannabis stocks? The AdvisorShares Pure US Cannabis ETF (MSOS) is the most direct cannabis ETF available to U.S. investors. Its largest holdings include Trulieve, Curaleaf, Green Thumb, Verano, Cresco, and TerrAscend — essentially a basket of the top picks from this list.
For investors who want cannabis exposure without concentration risk, MSOS offers a diversified approach.
If you’re building a broader portfolio alongside your cannabis positions, check out our guide to the best consumer staples stocks to buy for low-volatility balance in your portfolio.
Frequently Asked Questions About Marijuana Stocks in 2026
What is the best marijuana stock to buy in 2026?
Green Thumb Industries (GTBIF) is widely considered the best marijuana stock in 2026 due to its consistent profitability, strong cash flow, and conservative balance sheet. It’s the highest-quality operator in the U.S. cannabis sector.
Are marijuana stocks a good investment right now?
Cannabis stocks carry high risk but significant upside, especially in 2026 with U.S. federal rescheduling potentially removing the 280E tax burden. Focus on companies with strong fundamentals — not just legalization speculation.
What is the MSOS ETF and should I buy it?
MSOS is the AdvisorShares Pure US Cannabis ETF — the most popular cannabis ETF for U.S. investors. It holds the top MSOs including Trulieve, Green Thumb, Curaleaf, and Verano, making it a diversified option for cannabis exposure without single-stock risk.
Will marijuana stocks go up if federal rescheduling happens?
Federal rescheduling to Schedule III would eliminate the 280E tax burden, instantly improving profitability across all major MSOs. Most analysts expect a significant positive price reaction in cannabis stocks if rescheduling is finalized by the DEA.
What does 280E mean for cannabis investors?
Section 280E of the IRS tax code prevents cannabis companies from deducting normal business expenses, creating an effective tax rate far higher than other industries. Rescheduling would remove this burden entirely and dramatically improve MSO earnings.
Is Curaleaf or Green Thumb a better investment?
Green Thumb is the better quality investment with proven profitability, while Curaleaf offers greater scale and international exposure. For conservative investors, Green Thumb is the safer pick. For those wanting maximum federal reform upside, Curaleaf has the larger U.S. footprint.
What is the best cannabis stock for beginners?
For beginners, the MSOS ETF provides diversified cannabis exposure without the risk of betting on a single company. Among individual stocks, Green Thumb Industries is the most beginner-friendly choice due to its financial stability and profitability track record.
How do I buy marijuana stocks in the US, UK, Canada, or Australia?
Most cannabis stocks trade OTC in the U.S. with tickers ending in ‘F’, or on Canadian exchanges like the CSE. Investors in the UK, Canada, and Australia can access these through international brokers or platforms that support OTC and Canadian listings.
Is Trulieve a good cannabis stock to buy?
Trulieve is one of the strongest cannabis stocks in 2026 due to its dominant Florida market position, free cash flow generation, and massive upside potential if Florida expands recreational cannabis. It’s the top holding in the MSOS ETF.
What are the biggest risks of investing in marijuana stocks?
The biggest risks include ongoing federal prohibition in the U.S., price compression in mature cannabis markets, high effective tax rates from 280E, limited banking access, and the possibility that federal reform moves slower than the market expects.
Conclusion
The best marijuana stocks to buy in 2026 share one thing in common: they’ve survived the industry’s brutal growing pains and come out the other side with real fundamentals. Whether you go with the quality and consistency of Green Thumb Industries, the scale of Curaleaf, or the Florida asymmetry of Trulieve, the key is buying businesses — not lottery tickets.
Federal rescheduling won’t happen overnight. But the companies on this list are built to generate value with or without it. And if the regulatory environment does shift, they’ll be the first to benefit.
The window to position yourself ahead of the biggest potential catalyst in cannabis history may be closing. Do your research, diversify wisely, and think long term.
Disclosure: The content on this page was produced with AI writing assistance under the editorial direction of a licensed Electrical Engineering practitioner and certified investor in different markets with over a decade of experience. All articles are reviewed and approved by the author before publication.
